JSC Grindeks’ subsidiary in Lithuania Ltd Grindeks Kalceks has received the “Strongest in Lithuania 2026” (Stipriausi Lietuvoje) recognition, confirming the company’s financial stability, reliability and responsible business practices.
“Strongest in Lithuania” is an independent external assessment of a company’s creditworthiness and reliability and has been awarded in Lithuania since 2011. The certificate confirms that a company maintains a sound financial position, fulfils its tax obligations on time, and settles its obligations to business partners and employees in a timely manner. It is awarded to companies with a strong business reputation that contribute to the development of the Lithuanian economy and promote an ethical business culture. In 2026, a total of 1,439 companies in Lithuania received the “Strongest in Lithuania” certificate.
Director of Ltd Grindeks Kalceks Aurimas Motiejūnas comments: “This recognition reflects the professional approach of our team and the values that guide our work every day. Our priority is to maintain a strong and trusted position in the Lithuanian pharmaceutical sector while continuing to grow responsibly and uphold high standards of business ethics. At the same time, patients remain at the centre of what we do – our aim is to provide effective and accessible solutions that contribute to better health and quality of life. The company attributes the recognition to the professionalism and commitment of its employees, as well as to the consistent implementation of the Grindeks Group’s core values. Every team member contributes to the company’s performance, long-term development and reputation as a reliable business partner.”
In 2025, the Lithuanian subsidiary was also recognised by Creditinfo as a “Reliable Employer”, further highlighting the company’s financial reliability and responsible approach as an employer.
About JSC Grindeks
JSC Grindeks is the parent company of the international pharmaceutical group Grindeks. The Group is engaged in the research, development, manufacturing and commercialization of original medicines, generic medicines and active pharmaceutical ingredients.
The Grindeks Group comprises JSC Grindeks and its subsidiaries, including JSC Kalceks in Latvia, JSC Tallinna Farmaatsiatehas in Estonia and HBM Pharma s.r.o. in Slovakia. In total, the Group includes 38 subsidiaries and 11 representative offices.
JSC Grindeks specializes in the development and manufacture of medicines in the therapeutic areas of cardiovascular diseases, central nervous system disorders, oncology, dermatology and diabetes. JSC Kalceks focuses on the development and manufacture of medicines for the hospital segment, while JSC “Tallinna Farmaatsiatehas” specializes in the manufacture of ointments.
The Group’s products are exported to more than 100 countries worldwide. Key export markets include the European Union, Australia, the United Arab Emirates, Israel and CIS countries.
